The 29th Japan-Korea Urological Congress

Program & Abstracts

Date
September 14 [Fri] – 15 [Sat], 2012

Venue
[Friday, September 14]
Castle Park Hotel
[Saturday, September 15]
Kagoshima Prefectural Citizens Exchange Center
Kagoshima, Japan

President
Masayuki Nakagawa, M.D., Ph.D.
Professor, Department of Urology
Kagoshima University, Kagoshima, Japan
# The 29th Japan-Korea Urological Congress

## Program & Abstracts

<table>
<thead>
<tr>
<th>Date</th>
<th>September 14[Fri]-15[Sat], 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Venue</strong></td>
<td></td>
</tr>
<tr>
<td>[Friday, September 14]</td>
<td>Castle Park Hotel</td>
</tr>
<tr>
<td>[Saturday, September 15]</td>
<td>Kagoshima Prefectural Citizens Exchange Center</td>
</tr>
<tr>
<td><strong>President</strong></td>
<td>Masayuki Nakagawa, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td>Professor, Department of Urology</td>
</tr>
<tr>
<td></td>
<td>Kagoshima University, Kagoshima, Japan</td>
</tr>
</tbody>
</table>
CONTENTS

Message from the Congress President .......................... 1
Congress History .................................................................. 2
Congress Committee ...................................................... 3
Congress Information ....................................................... 4
Instruction for Chairpersons & Speakers ........................ 5
Floor Guide ........................................................................ 7
Congress Schedule .......................................................... 10

Scientific Program

Evening Seminar 1 ......................................................... 17
Evening Seminar 2 ........................................................ 25
Luncheon Seminar 1 ...................................................... 33
Luncheon Seminar 2 ....................................................... 39
Satellite Seminar 1 ........................................................ 45
Satellite Seminar 2 ........................................................ 53

Podium Session Program ............................................... 64

Abstracts

Podium Session 1 (Oncology 1) ..................................... 73
Podium Session 2 (Basic Research 1) ............................ 79
Podium Session 3 (Oncology 2) ..................................... 85
Podium Session 4 (Basic Research 2) ............................ 91
Podium Session 5 (Endourology) .................................. 97
Podium Session 6 (Basic Research 3) ............................ 106
Podium Session 7 (Miscellaneous) ............................... 115
Message from the congress president

Dear Colleagues:

It is my great honor to host the 29th Japan-Korea Urological Congress in Kagoshima, Japan. I cordially invite all of urologists and co-medical staffs in both countries to the congress held in September 14 to 15, 2012.

The main topics of this year’s congress are oncology, endourology, overactive bladder and basic research. We warmly welcome many papers in these fields. In the congress, we will have lectures and seminars focusing on current situation and controversy of urological diseases in both countries. I hope that urologists from each country can discuss the current topics and controversial issues fruitfully and share the latest information on urologic disease. Furthermore, I hope to extend our mutual friendship through the congress, especially in young urologists.

Kagoshima city is the capital of Kagoshima Prefecture, located at the southern-most tip of Kyushu. It is the largest city in southern Kyushu with a population of 600,000 and has been blessed with a mild climate and an abundance of hot springs. The majestic view of Mt Sakurajima, one of the world’s most active volcanoes, dominates the city’s landscape, towering over the beautiful Kinko Bay. There are many magnificent sightseeing spots in Kagoshima Prefecture. For example, Yakushima is an island surrounded by cobalt blue ocean and covered with ancient Yakusugi cedar trees. Yakushima’s magnificent natural beauty has gained it the title of “World Heritage”. Ibusuki is also famous for its natural sand hot springs.

The congress venue is Castle park hotel and Kagoshima Prefectural Citizens Exchange Center which are located in the center of Kagoshima city.

I hope that you will enjoy the scientific program and take full advantage of our sightseeing spots, nature, luxurious hot springs and good mouth-watering cuisine in Kagoshima.

Masayuki Nakagawa, M.D., Ph.D.
President of the 29th Japan-Korea Urological Congress
# Congress History

<table>
<thead>
<tr>
<th>No.</th>
<th>Location</th>
<th>Topic</th>
<th>Date</th>
<th>President</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>Kobe</td>
<td>Urolithiasis</td>
<td>Dec. 15</td>
<td>Joji Ishigami</td>
</tr>
<tr>
<td>2nd</td>
<td>Seoul</td>
<td>Bladder Cancer</td>
<td>Oct. 4</td>
<td>Young Kyoon Kim</td>
</tr>
<tr>
<td>3rd</td>
<td>Tokyo</td>
<td>Prostate Tumor</td>
<td>Nov. 28</td>
<td>Toyohei Machida</td>
</tr>
<tr>
<td>4th</td>
<td>Jeju</td>
<td>Pediatric Urology</td>
<td>Nov. 20</td>
<td>Young Kyoon Kim</td>
</tr>
<tr>
<td>5th</td>
<td>Kyoto</td>
<td>STD, Urolithiasis, Urinary Diversion</td>
<td>Nov. 26</td>
<td>Osamu Yoshida</td>
</tr>
<tr>
<td>6th</td>
<td>Busan</td>
<td>Renal Failure, RCC</td>
<td>Oct. 14</td>
<td>Jong Byung Yoon</td>
</tr>
<tr>
<td>7th</td>
<td>Fukuoka</td>
<td>UTI, Urinary Incontinence</td>
<td>Sep. 1</td>
<td>Joichi Kumazawa</td>
</tr>
<tr>
<td>8th</td>
<td>Yuseong</td>
<td>Nonvesical Urothelial Tumor, Impotence</td>
<td>Sep. 14</td>
<td>Sung Kun Koh</td>
</tr>
<tr>
<td>9th</td>
<td>Tokyo</td>
<td>BPH, Adrenal Disorder</td>
<td>Sep. 12</td>
<td>Yoshio Aso</td>
</tr>
<tr>
<td>10th</td>
<td>Seoul</td>
<td>Superficial Bladder Tumor, Male Infertility</td>
<td>Sep. 11</td>
<td>Soo Eung Chai</td>
</tr>
<tr>
<td>11th</td>
<td>Nara</td>
<td>Invasive Bladder Tumor Endourology Including ESWL</td>
<td>Sep. 10</td>
<td>Eigoro Okajima</td>
</tr>
<tr>
<td>12th</td>
<td>Gwangju</td>
<td>Prostate Cancer, Pediatric Urology</td>
<td>Sep. 16</td>
<td>Byung Kap Min</td>
</tr>
<tr>
<td>13th</td>
<td>Osaka</td>
<td>RCC, Voiding Dysfunction Including Incontinence</td>
<td>Sep. 14</td>
<td>Toshihiko Kotake</td>
</tr>
<tr>
<td>14th</td>
<td>Daegu</td>
<td>Prostatic Diseases, Endourology Including Laparoscopic Surgery</td>
<td>Jun. 21</td>
<td>Sae Kook Chang</td>
</tr>
<tr>
<td>15th</td>
<td>Tokyo</td>
<td>Advanced Prostate Cancer, Testicular Tumor, Impotence</td>
<td>Sep. 12</td>
<td>Makoto Miki</td>
</tr>
<tr>
<td>16th</td>
<td>Jeju</td>
<td>Bladder Cancer, Prostate Cancer, BPH, UTI</td>
<td>Sep. 11</td>
<td>Moo Sang Lee</td>
</tr>
<tr>
<td>17th</td>
<td>Tokyo</td>
<td>Prostate Cancer, Erectile Dysfunction</td>
<td>Sep. 22-23</td>
<td>Hideyuki Akaza</td>
</tr>
<tr>
<td>18th</td>
<td>Seoul</td>
<td>Urolithiasis, Urologic Cancer</td>
<td>Sep. 14-15</td>
<td>Sung Won Kwon</td>
</tr>
<tr>
<td>19th</td>
<td>Fukuoka</td>
<td>Urologic Cancer, Infectious Diseases</td>
<td>Sep. 27-28</td>
<td>Seiji Naito</td>
</tr>
<tr>
<td>20th</td>
<td>Busan</td>
<td>Prostate Cancer &amp; BPH, Laparoscopy, Female Urology</td>
<td>Oct. 3-4</td>
<td>Jin Han Yoon</td>
</tr>
<tr>
<td>21st</td>
<td>Sapporo</td>
<td>Urologic Oncology Voiding Dysfunction, Reconstructive Urology</td>
<td>Aug. 27-28</td>
<td>Taiji Tsukamoto</td>
</tr>
<tr>
<td>22nd</td>
<td>Jeonju</td>
<td>Urologic Oncology, Voiding Dysfunction &amp; Urinary Incontinence, Men’s Health, Urolithiasis</td>
<td>Sep. 9-10</td>
<td>Young Kyung Park</td>
</tr>
<tr>
<td>23rd</td>
<td>Nara</td>
<td>Uro-oncology, Urodynamics, Endourology</td>
<td>Sep. 22-23</td>
<td>Yoshihiko Hirao</td>
</tr>
<tr>
<td>24th</td>
<td>Cheongju</td>
<td>Uro-oncology, Voiding Dysfunction Erectile Dysfunction Pediatric Urology</td>
<td>Oct. 5-6</td>
<td>Wun-Jae Kim</td>
</tr>
<tr>
<td>25th</td>
<td>Okayama</td>
<td>Urogynecology, Endourology, Oncology, Molecular Urology</td>
<td>Sep. 26-27</td>
<td>Hiromi Kumon</td>
</tr>
<tr>
<td>26th</td>
<td>Seoul</td>
<td>Oncology, Endourology and Laparoscopic surgery, Pediatric Urology, Voiding Dysfunction</td>
<td>Sep. 18-19</td>
<td>Hwang Choi</td>
</tr>
<tr>
<td>27th</td>
<td>Kyoto</td>
<td>Urological Oncology, Endourology/Laparoscopy, Voiding Dysfunction</td>
<td>Sep. 10-11</td>
<td>Osamu Ogawa</td>
</tr>
<tr>
<td>28th</td>
<td>Suwon</td>
<td>Oncology, Andrology, Endourology, Voiding Dysfunction</td>
<td>Sep 16-17</td>
<td>Sae Chul Kim</td>
</tr>
<tr>
<td>29th</td>
<td>Kagoshima</td>
<td>Oncology, Endourology, Overactive Bladder, Basic Research</td>
<td>Sep 14-15</td>
<td>Masayuki Nakagawa</td>
</tr>
</tbody>
</table>
Congress Committee

President:
Masayuki Nakagawa, M.D., Ph.D.
Professor and Chairman, Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University

Organizing Committee

• Honorary Members (Institution at the retirement)
  Yoshio Aso (The University of Tokyo)
  Soo Eung Chai (Sungkyunkwan University)
  Hwang Choi (Seoul National University)
  Sadao Kamidono (Kobe University)
  Kazuki Kawabe (The University of Tokyo)
  Young Kyoon Kim (Seoul National University)
  Sung Kun Koh (Korea University)
  Toshihiko Kotake (Osaka Medical Center for Cancer & Cardiovascular Diseases)
  Joichi Kumazawa (Kyushu University)
  Takashi Kurita (Kinki University)
  Sung Won Kwon (Ewha Womans University)

• Japanese Members
  Hideyuki Akaza (Research Center for Advanced Science and Technology, The University of Tokyo)
  Shin Egawa (Jikei University)
  Yoshihiko Hirao (Osaka Gyomeikan Hospital)
  Yoshiyuki Kakehi (Kagawa University)
  Hiromi Kumon (Okayama University)
  Seiji Naito (Kyushu University)
  Masayuki Nakagawa (Kagoshima University)
  Osamu Ogawa (Kyoto University)
  Taiji Tsukamoto (Sapporo Medical University)

• Korean Members
  Han Yong Choi (Sungkyunkwan University)
  Tae Kon Hwang (Seoul St. Mary’s Hospital)
  Wun-Jae Kim (Chungbuk National University)
  Joung Sik Rim (Wonkwang University)
  Soo Bang Ryu (Chonnam National University)
  Jae Mann Song (Yonsei University Wonju Christian Hospital)
  Jin Han Yoon (Dong-A University)
  Jae-Seung Paick (Seoul National University)
  Kyung Do Kim (Chung-Ang University)
  Chun IL Kim (Dongsan Medical Center, Keimyung University)

Michiyuki Usami (Osaka Medical Center for Cancer & Cardiovascular Diseases)
Osamu Yoshida (Kyoto University)
Sae Chul Kim (Chung-Ang University Medical Center)
Congress Information

Date: September 14-15, 2012

Place: September 14: Castle Park Hotel
       41-1 Shinshoin-cho Kagoshima 890-8586, Japan
       September 15: Kagoshima Prefectural Citizens Exchange Center
       14-50 Yamashita-cho Kagoshima 892-0816, Japan

President: Masayuki Nakagawa, M.D., Ph.D.
           Professor and Chairman, Department of Urology, Graduate School of Medical and Dental Sciences,
           Kagoshima University

Main Topics: Oncology, Endourology, Overactive bladder, Basic Research

Registration Desk / Registration Fee:

   Registration Desk  On September 14, 14:00-18:00, the registration desk will be open in front of
                    Pearl Hall Tenpyo.
                    On September 15, 8:30-15:00, the registration desk will be open at 2nd floor of
                    Kagoshima Prefectural Citizens Exchange Center.

   Registration Fee  Delegate: 10,000 yen or 100,000 won
                     (Lunch and Banquet fees are included)
                     Accompanying person: free

Social Program:

1. Mini Concert and Welcome Party (for all participants): September 14th from 18:30 to 21:30,
   Royal Garden (2nd Floor, Castle Park Hotel)

2. Organizing Committee Meeting (members only): September 15th from 12:00 to 13:00, Main
   training room (3rd Floor, Kagoshima Prefectural Citizens Exchange Center)

3. Ladies Bus Tour (subscribers only): September 15th, (pickup time) 9:30 a.m. and (pickup point)
   the hotel entrance.

4. Sightseeing Bus Tour (for all participants): September 15th, (pickup time) 16:00 and (pickup
   point) in front of Kagoshima Prefectural Citizens Exchange Center.

5. Farewell Party (for all participants): September 15th from 18:30 to 21:00, Sakurajimanoma
   (2nd Floor, Castle Park Hotel).

Shuttle Bus Service:

on September 15 (Saturday), shuttle buses will start at 8:20 and 8:40 from Castle Park Hotel to
Kagoshima Prefectural Citizens Exchange Center.

Airport shuttle bus:

on September 16 (Sunday), a shuttle bus will start at 13:30
from Castle Park Hotel to Kagoshima International Airport.

Secretary General:

Hideki Enokida, M.D., Ph.D. and Yousuke Uchida, M.D.
Department of Urology, Graduate School of Medical and Dental Sciences
Kagoshima University
8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
Phone: +81-99-275-5395; Fax: +81-265-9727
E-mail: jkuro29@m2.kufm.kagoshima-u.ac.jp
Website: http://jkuro29.umin.jp/
Instruction for Chair persons & Speakers

Instruction for Chair persons

1) All chairpersons are asked to be in the lecture room no later than 15 minutes prior to the beginning of the session.

2) Chairpersons should make efforts to maintain the time schedule in cooperation with time keeper, and give warning speakers if needed.

3) Presentation time for one speaker of sponsored seminars (Evening Seminars, Luncheon Seminars, and Satellite Symposia) is 30 minutes including discussion. Presentation time for other general papers is 7 minutes in total (5 min. presentation +2 min. discussion).

Instruction for Speakers

- Preparation

1) All papers should be made for oral presentation. Only digital presentations will be possible during the congress, and all speakers are requested to bring CD-ROM/USB-Flash Memory for the presentation or bring their own notebook computer.

2) In the venue, we will prepare floor computer systems (Windows 7 and Mac OS X) for the presentations.


4) For Macintosh users, application software of the presentation data must be PowerPoint 2008/2011 and Keynote’09, and the operation system is limited to OS X.

5) You should save the presentation file with a filename as ‘paper No._speaker’s name.ppt’ (ex. 0-1._ Jang Geun-seok.ppt). Paper No. for each presentation had been sent by email to the speaker.

6) Please bring your presentation file sorely saved in CD-ROM/USB-Flash Memory. Any other files should be deleted from CD-ROM/USB-Flash Memory to avoid unexpected errors. You should make a back-up in cases of malfunctions.

7) When you set a log-in password on your own notebook computers, please tell the operator in the venue about that and unlock your computer before your presentation.

8) It is also required for speakers using their own notebook computers to bring AC adapter during the presentation. If your computer does not have D-sub 15 adapter, you must bring an interface adapter by yourself (please see below).

9) Please deselect screen savor function and energy-saving mode before your presentation.

10) Please make sure to check your CD-ROM/USB-Flash Memory by using latest anti-virus software to avoid computer virus infection to the host computer system in the venue.
- **Preview and Presentation**

1) All speakers are requested to stop by PC Preview Desk at Congress venue and review the presentation data until 60 minutes before your presentation. Full-time staff will help you at PC Preview Desk.

2) Presentation time for one speaker of sponsored seminars (Evening Seminars, Luncheon Seminars, and Satellite Symposia) is 30 minutes including discussion. Presentation time for other general papers is 7 minutes in total (5 min. presentation +2 min. discussion). Please keep the time to ensure smooth proceedings, according to chairpersons’ moderation.

3) You can control your presentation by using a computer mouse and a key pad for PowerPoint on the desk for speaker.

4) When you bring your own notebook computer, please pick it up at the PC control desk in the venue after your presentation.

5) When you bring CD-ROM/USB-Flash Memory for the presentation, please keep it for a back-up even after your slide submission. After your presentation, we promise you to delete the files in the venue computer.
Welcome Party
September 14 18:30~

Farewell Party
September 15 18:30~

Registration

Evening seminar 1・2

Pearl Hall
Tenpyo

Sakurajima

Royal Garden

shuttle bus stop

Entrance

Entrance
Floor Guide

※Please take the east EV, if you want to go to 3Floor.
### Congress Schedule

**September 14, 2012 (Friday)**

**Pearl Hall Tenpyo at Castle Park Hotel (Level 4F)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00–16:00</td>
<td>Registration open &amp; Slide Submission</td>
</tr>
</tbody>
</table>
| 16:00–17:00      | **Evening Seminar 1**  
Radical prostatectomy: where are we going?  
Chairpersons:  
Seiji Naito (Kyushu University, Japan)  
Joung Sik Rim (Wonkwang University, Korea)  
Speakers:  
Shin Egawa (Jikei University, Japan)  
Hanjong Ahn (Asan Medical Center, Korea)  
Sponsor:  
Takeda Pharmaceutical Company Ltd. |
| 17:00–18:00      | **Evening Seminar 2**  
Chairpersons:  
Yoshiyuki Kakehi (Kagawa University, Japan)  
Han Yong Choi (Sungkyunkwan University, Korea)  
Speakers:  
Mototsugu Oya (Keio University, Japan)  
Young Deuk Choi (Yonsei University. Severance Hospital, Korea)  
Sponsor:  
Novartis Pharmaceuticals Corporation |

**Royal Garden at Castle Park Hotel (Level 2F)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 18:30–19:00      | **Mini Opera Concert**  
Performed by Prof. Suguru Yonezawa                                   |
| 19:00–21:30      | **Welcome Party**                                                     |
### September 15, 2012 (Saturday)

**Main Hall & Annex Hall, Kagoshima Prefectural Citizens Exchange Center (Level 2F)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–09:00</td>
<td>Registration open &amp; Slide Submission</td>
</tr>
<tr>
<td>09:00–09:10</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>09:10–09:55</td>
<td>Podium Session 1</td>
</tr>
<tr>
<td></td>
<td><strong>Oncology 1: Prostate Cancer / Renal Cell Carcinoma</strong></td>
</tr>
<tr>
<td></td>
<td>Chairpersons:</td>
</tr>
<tr>
<td></td>
<td>Youichi Arai (Tohoku University, Japan)</td>
</tr>
<tr>
<td></td>
<td>Joung Sik Rim (Wonkwang University, Korea)</td>
</tr>
<tr>
<td>09:55–10:40</td>
<td>Podium Session 3</td>
</tr>
<tr>
<td></td>
<td><strong>Oncology 2: Bladder Cancer / Others</strong></td>
</tr>
<tr>
<td></td>
<td>Chairpersons:</td>
</tr>
<tr>
<td></td>
<td>Hideyuki Akaza (Research Center for Advanced Science and Technology, Japan)</td>
</tr>
<tr>
<td></td>
<td>Jae Mann Song (Yonsei University Wonju Christian Hospital, Korea)</td>
</tr>
<tr>
<td>10:40–10:55</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:55–12:00</td>
<td>Podium Session 5</td>
</tr>
<tr>
<td></td>
<td><strong>Endourology: Donor nephrectomy /Prostatectomy / Others</strong></td>
</tr>
<tr>
<td></td>
<td>Chairpersons:</td>
</tr>
<tr>
<td></td>
<td>Toshiro Terachi (Tokai University, Japan)</td>
</tr>
<tr>
<td></td>
<td>Choung Soo Kim (Asan Medical Center, Korea)</td>
</tr>
<tr>
<td></td>
<td>Podium Session 6</td>
</tr>
<tr>
<td></td>
<td><strong>Basic Research 3: Bladder Cancer / Others</strong></td>
</tr>
<tr>
<td></td>
<td>Chairpersons:</td>
</tr>
<tr>
<td></td>
<td>Chikara Oyama (Hirosaki University, Japan)</td>
</tr>
<tr>
<td></td>
<td>Hanjong Ahn (Asan Medical Center, Korea)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 12:00~12:30  | **Podium Session 7**  
**Miscellaneous**  
Chairpersons:  
Hidehiro Kakizaki (Asahikawa Medical University, Japan)  
Duk-Yoon Kim (Catholic University of Daegu, Korea) | **Main Hall**                                  |
| 12:00~13:00  | **Main training room, Kagoshima Prefectural Citizens Exchange Center (Level 3F)** | **Organizing Committee Meeting**              |
| 12:35~13:35  | **Luncheon Seminar 1**  
Up-to-date management of overactive bladder  
Chairpersons:  
Taiji Tsukamoto (Sapporo Medical University, Japan)  
Jae-Seung Paick (Seoul National University, Korea)  
Speakers:  
Hidehiro Kakizaki (Asahikawa Medical University, Japan)  
Duk-Yoon Kim (Catholic University of Daegu, Korea)  
Sponsor:  
Astellas Pharma Inc. | **Main Hall**                                  |
|              | **Luncheon Seminar 2**  
The battle against invasive bladder cancer: what is the next step?  
Chairpersons:  
Toshiyuki Kamoto (Miyazaki University, Japan)  
Kyung Do Kim (Chung-Ang University, Korea)  
Speakers:  
Chikara Oyama (Hirosaki University, Japan)  
Wun-Jae Kim (Chungbuk National University Hospital, Korea)  
Sponsor:  
Eli Lilly Japan | **Annex Hall**                                 |
<p>| 13:35~13:50  | <strong>Coffee Break</strong>                                                       |                                               |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:50–14:50</td>
<td><strong>Satellite Symposium 1</strong>&lt;br&gt;Treatment strategy for BPH/male LUTS in 2012.</td>
</tr>
<tr>
<td></td>
<td>Chairpersons:&lt;br&gt;Yoshihiko Hirao (Osaka Gyoumeikan Hospital, Japan)&lt;br&gt;Tae Kon Hwang (Seoul St. Mary’s Hospital)</td>
</tr>
<tr>
<td></td>
<td>Speakers:&lt;br&gt;Mitsuhiko Yokoyama (Kawasaki Medical University, Japan)&lt;br&gt;Ji Youl Lee (Seoul St. Mary’s Hospital, Korea)</td>
</tr>
<tr>
<td></td>
<td>Sponsor:&lt;br&gt;AsahiKASEI Pharma.</td>
</tr>
<tr>
<td>14:50–15:50</td>
<td><strong>Satellite Symposium 2</strong>&lt;br&gt;Therapeutic approaches in the management of castration-resistant prostate cancer.</td>
</tr>
<tr>
<td></td>
<td>Chairpersons:&lt;br&gt;Osamu Ogawa (Kyoto University, Japan)&lt;br&gt;Soo Bang Ryu (Chonnam National University, Korea)</td>
</tr>
<tr>
<td></td>
<td>Speakers:&lt;br&gt;Nobuo Shinohara (Hokkaidou University, Japan)&lt;br&gt;Choung Soo Kim (Asan Medical Center, Korea)</td>
</tr>
<tr>
<td></td>
<td>Sponsor:&lt;br&gt;Sanofi-Aventis Japan</td>
</tr>
<tr>
<td>14:50–15:00</td>
<td><strong>Closing Ceremony</strong></td>
</tr>
<tr>
<td>16:00–18:00</td>
<td><strong>Sightseeing Bus Tour</strong></td>
</tr>
</tbody>
</table>

**Sakurajimanoma at Castle Park Hotel (Level 2F)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30–21:00</td>
<td><strong>Farewell Party</strong></td>
</tr>
</tbody>
</table>
Scientific Program
Evening Seminar 1

Radical prostatectomy: where are we going?

September 14, 16:00-17:00
(Pearl Hall Tenpyo)

Chairpersons:
Seiji Naito (Kyushu University)
Joung Sik Rim (Wonkwang University)

Speakers:

1. Shin Egawa (Jikei University)

2. Hanjong Ahn (Asan Medical Center)

Sponsored by
Takeda Pharmaceutical Company Ltd.
Chairpersons

Seiji Naito
Professor, Kyushu University

Subspecialties:
Urological oncology, Endourology

Brief Sketch:
1974- MD Kumamoto University, Faculty of Medicine
1974-1976 Resident, Department of Urology, Kyushu University Hospital, Fukuoka
1976-1980 Postgraduate Course in Pathology at Kyushu University
1980- PhD, Kyushu University
1980-1982 Medical Staff, Department of Urology, Hiroshima Red Cross Hospital, Hiroshima
1982-1984 Assistant Professor, Department of Urology, Faculty of Medicine, Kyushu University
1984-1986 Visiting Assistant Professor, Department Urology and Cell Biology, M.D. Anderson Hospital, University of Texas, Houston, Texas, USA
1986-1994 Assistant Professor, Department of Urology, Faculty of Medicine, Kyushu University
1994-1998 Associate Professor, Department of Urology, Faculty of Medicine, Kyushu University
1998-present Professor and Chairman, Department of Urology, Graduate School of Medical Sciences, Kyushu University

Joung Sik Rim, M.D., Ph.D.
Professor, Department of Urology, Wonkwang University
School of Medicine & Hospital

Subspecialties:
Uro-Oncology (Prostate, Bladder), Endourology

Brief Sketch:
1985- Professor, Wonkwang University
School of Medicine & Hospital
1997-1999 Executive Committee Member of Korean Urological Oncology Society
1997-2003 Executive Committee Member of Korean Endourological Society
1998-2002 Executive Board Member of Korean Urological Association
2001-2004 Director of Gunsan Medical Center of Wonkwang University Hospital
2003-2005 President of Korean Endourological Society
2006-2011 Director of Wonkwang University Hospital
2003- Council member of East Asian Society of Endourology
2006- Council member of Korean Endourological Society
2007-2010 Executive Committee Member of Korean Urological Oncology Society
2010- Council member of Korean Urological Oncology Society
2010- Active Committee member of Korea-Japan Urological Congress

The 29th Japan-Korea Urological Congress (Kagoshima, Japan)
Future perspective of radical prostatectomy

Shin Egawa
Jikei University School of Medicine

The treatment of prostate cancer has been affected by the emergence of minimally invasive techniques. Advances in laparoscopic and robotic technology along with sophisticated new ablative procedures have changed the way urologists approach patients with this malignancy. The increasing availability of robotic technology to urologists has expanded the role and indications for RARP (robot-assisted radical prostatectomy). Compared with the open approach, laparoscopic radical prostatectomy (LRP) and RARP have a similar outcome in terms of oncological as well as functional control, but potentially distinct favorable benefits in terms of blood loss, transfusion rates and minor complications, in the hands of experienced surgeons. Currently, collaborative research is underway to further improve the versatility and utility of robotics in surgery, as some scientists are working on miniaturizing the robots. It is possible that future robots will be smaller, more efficient and will perhaps be endowed with a bionic or haptic feedback technology to further bridge the gap of lack of tactile sensation. Robots will also provide radiologic imaging on the console. Further advances and refinements in the robotic instruments and technique of computer-assisted surgery may lead to the development of more single-port techniques.

Subspeciality
Prostate Cancer, Urological oncology, Laparoscopic Surgery

Brief sketch

1981  Graduate from Iwate Medical College, Morioka, Iwate, Japan
1981-1986  Resident at Department of Urology, Kitasato University School of Medicine
1988-1990  Research fellow, Baylor College of Medicine, USA
1990-1992  Research associate, Baylor College of Medicine, USA
2002-2004  Associate professor, Department of Urology, Kitasato University School of Medicine
2004 to Present  Professor and Chair, Department of Urology, Jikei University School of Medicine.
2010 to present  Chair, Scientific Committee, Urological Association of Asia
2011 to present  Deputy National Delegate of SIU
Radical prostatectomy: where are we going?

Hanjong Ahn, M.D. Ph. D.
Professor / Department of Urology, University of Ulsan College of Medicine
Director / Urologic Cancer Center, Asan Medical Center, Seoul, Korea

A rapid increase in incidence of prostate cancer in Western countries after introduction of PSA screening in clinical practice leads to soaring increase of performing radical prostatectomy, a gold standard of treatment for localized prostate cancer. However, such increase in incidence of prostate cancer brings the issue of overdiagnosis as well as overtreatment. Another issue relating to radical prostatectomy over last 10 years is the evolvement of a new less invasive treatment method, Da Vinci robot system, which has become popular markedly due to better functional outcome after robotic prostatectomy and aggressive marketing of the company. In this section, I will briefly address the above issues based on my personal experience.

1. Active surveillance vs. radical prostatectomy in low risk prostate cancer

The detection of low-risk prostate cancer (PCa) has increased considerably from 27.5% to 46.4% in US between 1990 and 2001 because of widespread use of PSA test [1]. PSA-based screening has been demonstrated to reduce the rate of PCa specific-death from 51% to 31% in ERSPC study [2]. Active surveillance (AS) is a solution to the widely acknowledged problems of overdiagnosis and overtreatment in PCa detected by PSA screening. However, the proportion of low risk PCa among total PCa is much lower in Asian countries, whereas the detection of high risk and advanced diseases have not significantly decreased yet even after introduction of PSA test [3-6]. In this respect, AS seems not to be necessary in Asian countries.

Since a subset of patients on AS had upgraded GS and extraprostatic extension (ECE) after radical prostatectomy (RP) [7-11], selection of proper patients for AS is mandatory. Although predicting factors of upgrading and upstaging were investigated in many studies [10, 12-14], the information from initial PSA and prostate biopsy was insufficient to predict upgrading and upstaging. In currently used AS criteria, there is a risk of missing significant disease. Better prediction tools are needed. Some investigators used prostate MRI as predicting factor for disease progression or hidden high-grade tumor [15-18]. However, the role of MRI in patients on AS has been not apparent yet.

The role of MRI was evaluated as a predictor of upgrade in Asan Medical Center. In 662 patients who underwent RP between 2007 and 2012, 205 (30.9%) patients with low-risk PCa were included. After RP, 53% of the low risk disease ended up upgraded. Age, PSA density and anterior location of index cancer on MRI were independent factor for prediction of GS upgrade in low-risk patients after RP (OR=1.062, p=0.002; OR=2.031, p=0.021; OR=2.479, p=0.027, respectively). In very low-risk patients, anterior location of index cancer on MRI was the only risk factor for upgrading (OR=5.333, p=0.034). It may be speculated that tumors in anterior location of the prostate gland easily failed to be detected by prostate biopsy. In our data, MRI had a substantial role in predicting GS
up upgrade after RP in candidates for AS. In patients with low risk disease, RP should be considered when the anterior tumor presents on MRI at initial diagnosis.

2. Can the robotic prostatectomy replace the open or laparoscopic RP?
In Robotic surgery, presence of 3-D magnification and tools that are able to duplicate hand movements with high accuracy, have allowed urologists to have short learning curves and improve functional outcome of RP [19]. As a result, the proportion of Robotic RP (RALP) has increased from 8% to 67% between 2004 and 2010 in US [20]. Then, can RALP replace the open or laparoscopic RP (LRP)? Meta-analysis about oncological outcome, urinary continence and potency rates after RALP was reported recently [21-23]. Positive surgical margin (PSM) rates were similar following RALP, open RP (ORP) and LRP. Better 12-mo potency rates after RALP was reported in comparison with RRP and a nonstatistically significant trend in favor of RALP was reported after comparison with LRP. After RALP, better 12-mo urinary continence recovery was reported in comparison with both RRP and LRP. RALP had another advantage including cosmetic improvement and decreased blood loss than ORP [24, 25]. However, oncological outcome of RALP is ongoing concern and the higher cost of RALP is another criticism. Bolenz et al. [26] reported that the cost was higher for RALP compared with LRP or ORP (RALP: $13,071, LRP: $10,877, ORP: $8,388), but the difference was greater in Korea because of lack of reimbursement from national health insurance for RALP. In Asan Medical Center, the mean total cost of RALP and ORP is $13,297 and $4,166. Another considerable point is that the patients who underwent RALP were more likely to be regretful and dissatisfied because of higher expectation of RALP as an “innovation” procedure [27]. The preoperative counseling is necessary to minimize regret and maximize satisfaction.
In data from Asan Medical Center, the proportion of RALP has increased from 38.0% to 69.4% since the introduction of Da Vinci robot in 2007. In analysis of functional outcomes, after initial cases, patients after RALP demonstrated faster recovery of urinary continence compared with ORP patients (median 1.6-mo vs. 4.3-mo). Potency recovery was more rapid in the RALP at all evaluation time points (median 9.8-mo vs. 24.7-mo). Overall PSM rate was similar between RALP and RRP (24.0 vs. 23.3%) and was not different according to pathologic T stage. Short-term (3-ys) biochemical recurrence was not different between RALP and ORP after controlling preoperative variables. Taken together, RALP was definitely better than ORP in functional outcomes. However, regarding oncological outcome, longer follow-up studies may elucidate the benefit of RALP compared with ORP.

Conclusion
In patients on AS, the prediction of upgrade is very important because that means patients with upgraded GS, have missed the chance of early treatment. Thus, the selection is crucial whether to perform AS or RP in patients with low risk disease. MRI may contribute to making a decision.
From recent data, RALP was better than ORP in terms of functional outcomes. However, regarding oncological outcome, longer follow-up studies are necessary. The higher cost of RALP is another obstacle to accept RALP as a standard procedure of RP.

References
### Subspeciality
Urological Oncology

### Education
<table>
<thead>
<tr>
<th>Date</th>
<th>Program/Institution</th>
</tr>
</thead>
</table>
| Feb. 26, 1992 | Graduate Postgraduate School  
Seoul National University, Seoul, Korea  
(Doctor of Philosophy in Medicine) |
| Feb. 26, 1982 | Graduate College of Medicine  
Seoul National University, Seoul, Korea  
(Doctor of Medicine) |

### Training
<table>
<thead>
<tr>
<th>Year</th>
<th>Program/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989-1990</td>
<td>Fellowship / Dept. of Urology, Asan Medical Center</td>
</tr>
<tr>
<td>1983-1986</td>
<td>Residency / Dept. of Urology, Seoul National University Hospital</td>
</tr>
<tr>
<td>1982-1983</td>
<td>Internship / Seoul National University Hospital</td>
</tr>
</tbody>
</table>

### Certifications and License
<table>
<thead>
<tr>
<th>Year</th>
<th>Certification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1986</td>
<td>Korean Board of Urology</td>
</tr>
<tr>
<td>1982</td>
<td>Korean License of Medical Doctor</td>
</tr>
<tr>
<td>2010</td>
<td>Institutional Review Board GCP Training for Investigators</td>
</tr>
<tr>
<td>2011</td>
<td></td>
</tr>
</tbody>
</table>

### Academic Positions
<table>
<thead>
<tr>
<th>Year</th>
<th>Position/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000-present</td>
<td>Professor/ Dept. of Urology/University of Ulsan College of Medicine</td>
</tr>
<tr>
<td>1996-1999</td>
<td>Associate Professor/Dept. of Urology/University of Ulsan College of Medicine</td>
</tr>
<tr>
<td>1992-1995</td>
<td>Assistant Professor/Dept. of Urology/University of Ulsan College of Medicine</td>
</tr>
<tr>
<td>1993-1994</td>
<td>Visiting Scholar/Dept. of Urology/Northwestern University/Chicago, Illinois, USA</td>
</tr>
<tr>
<td>1990-1991</td>
<td>Instructor/Dept. of Urology/University of Ulsan College of Medicine</td>
</tr>
</tbody>
</table>

### Memberships
- Korean Medical Association
- Korean Urological Association
- Korean Urological Oncology Society
- American Urological Association
- Urological Research Society
Evening Seminar 2

Metastatic renal cell carcinoma: current management and controversial issues

September 14, 17:00-18:00
(Pearl Hall Tenpyo)

Chairpersons:
Yoshiyuki Kakehi (Kagawa University)
Han Yong Choi (Sungkyunkwan University)

Speakers:

1 Mototsugu Ohya (Keio University)

2 Young Deuk Choi (Yonsei Univ. Severance Hospital)

Sponsored by
Novartis Pharmaceuticals Corporation
Chairpersons

Department of Urology, Kagawa University Faculty of Medicine

Subspecialties:
Urologic Oncology, Laparoscopic Surgery, Kidney Transplantation

Brief Sketch:
1981 Graduated from Kyoto University Faculty of Medicine
1989 Graduated from Kyoto University Graduate School of Medicine
2000 Associate Professor, Department of Urology, Kyoto University Graduate School of Medicine
2001- Professor and Chairman, Department of Urology, Kagawa University Faculty of Medicine

Han Yong Choi, M.D., Ph.D.
Samsung Medical Center, Seoul, Korea.
Vice President, Medical Affair, Sungkyunkwan University
Professor, Department of Urology, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine

Subspecialties:
Urological Oncology, Prostate Cancer, Bladder Cancer, Kidney Cancer

Brief Sketch:
1971 -1977 Seoul National University College of Medicine
1977 -1982 Resident, Urology, Seoul National University Hospital
1985 -1992 Urologist, Masan Koryo General Hospital
1992 -1994 Fellow, Urology, Duke University Medical Center
1994 - Urologist, Samsung Medical Center
1997 - Professor, Urology, Sungkyunkwan University School of Medicine
1999 -2003 Urologist-in-Chief, Samsung Medical Center,
2004 -2008 Executive Vice President, Samsung Medical Center
2006 -2008 President of the Korean Urological Oncology Society
2008 -2012 President & CEO, Samsung Seoul Hospital
2012 - Vice President, Medical Affair, Sungkyunkwan University

Membership of International Scientific Association
1. American Urological Association (AUA) : Corresponding Member
2. European Association of Urology(EAU): Corresponding Member
3. Urological Association of Asia: Active Member
Resistance to molecular targeted therapy in metastatic renal cell carcinoma

Mototsugu Oya, MD
Department of Urology, Keio University School of Medicine

Novel molecular findings in cancer have led to the opening for the era of molecular targeted therapy. Molecular targeted agents are currently treatments of choice in metastatic renal cell carcinoma (mRCC). RCC is classified pathologically into the three major types, i.e. clear cell, papillary, and chromophobe. Clear cell is about 80% of all types. Clear cell RCC is well known for its hypervascularity. Most important molecular disorder of clear cell type RCC is VHL tumor suppressor gene. The VHL tumor suppressor protein acts as the substrate recognition component of an ubiquitin E3 ligase that targets protein degradation of HIF-α subunits. Therefore, HIF is constitutively activated in clear cell RCC. HIF induces the expression of vascular endothelial growth factor (VEGF). The angiogenesis of clear cell RCC depends on VEGF. Sorafenib and sunitinib are anti-angiogenic agents called as tyrosine kinase inhibitors (TKIs). TKIs target vascular endothelial growth factor (VEGF) receptor. Mammalian target of rapamycin (mTOR) inhibitors are another class of agents that are active for mRCC. mTOR inhibitors induce cell cycle arrest and block the proliferation in cancer cells whose mTOR is activated. Furthermore, mTOR inhibitors are known to down-regulate the induction of HIF. As a result, mTOR inhibitors have an anti-angiogenesis activity. However, the shrinkage of the tumor by mTOR inhibitors is modest. The act of mTOR inhibitors on RCC is considered cytostatic. This is in contrast to the first line therapy exerting robust cytotoxic activity by TKIs. Based on the results of global phase 3 clinical trials temsirolimus is indicated as the first line therapy for RCC patients with poor prognosis or non-clear subtypes, whereas everolimus as the second line for those refractory to TKIs.

TKIs revolutionized the treatment of RCC. However, subsets of patients fail to achieve any tumor shrinkage. For these patients, biomarkers to predict the effectiveness of the agents are necessary. However, there are no such predictive biomarkers available at present. Other patients have drastic and prolonged effects, followed inevitably by progression. Therefore, sequential therapy is necessary for the patients. Patients whose disease progresses during initial TKI therapy may continue treatment with a different TKI or they may switch to treatment with mTOR inhibitor. For the optimization of the sequential therapy, mechanisms underlying resistance should be elucidated. However, the underlying mechanism of the adaptive resistance is not clearly understood. It is suggested that revascularization consequent to up-regulation of alternative pro-angiogenic cytokines including fibroblast growth factor (FGF), IL-8 and angiopoietin may play a role. Another serious clinical problem in TKI is, when stopped, the patients likely to have aggressive disease. The rebound phenomenon observed in these patients treated by TKIs and recur suggest that surviving cancer cells are more potent in proliferation. The adaptive resistance by malignant phenotype of the cancer paid much attention. Cancer cells adapt the microenvironment by remodeling stroma or may reduce dependence on
angiogenesis and evade by up-regulating pathways involved in survival, invasiveness and metastases. Elucidating molecular phenotype of the resistant cancer cells is necessary for exploring the next stage targeting molecules. Invasion and metastasis are tightly related with epithelial-mesenchymal transition (EMT) and/or cancer stem cells. Another complex issue regarding resistance is that re-challenged TKI exerts some clinical benefits. It is widely believed, at least in the field of chemotherapy, that when a tumor is resistant it remains so permanently. This concept is not applicable to TKIs.

When we consider the sequential therapy or novel targeted therapy to eradicate RCC cancer cells, understanding the mechanism of both the sensitivity and the acquisition of resistance is utmost important.

Subspeciality
oncology

Brief sketch

<table>
<thead>
<tr>
<th>Year</th>
<th>Position and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1987 Mar/</td>
<td>M.D. Keio University, School of Medicine, Tokyo, Japan</td>
</tr>
<tr>
<td>Jan/1995-Mar/1996</td>
<td>Postdoctoral fellow, Department of Urology, New York Medical College, USA</td>
</tr>
<tr>
<td>Jan/1997-Sep/1998</td>
<td>Postdoctoral fellow, Department of Urology, Duesseldorf University, Germany</td>
</tr>
<tr>
<td>Oct/1998-Mar/2001</td>
<td>Medical Staff, Department of Urology, Keio University Hospital</td>
</tr>
<tr>
<td>Apr/2001-Jun/2007</td>
<td>Assistant Professor, Department of Urology, Keio University School of Medicine</td>
</tr>
<tr>
<td>Aug/2007-present</td>
<td>Professor and Chairman, Department of Urology, Keio University School of Medicine</td>
</tr>
</tbody>
</table>
Treatment of metastatic renal cell carcinoma

Young Deuk Choi  
Yonsei University

Introduction
The only curative therapeutic option for renal carcinoma is the complete resection of the primary tumor. But, some patients have metastatic disease at the time of diagnosis and a substantial number of patients develop systemic disease progression regardless an initial organ confined tumor.

In the past, patients with metastatic urological cancer were considered incurable and were not candidates for surgical treatment in management of metastases. Systemic chemotherapy was the mainstay of treatment in those metastatic cases. In the dynamic field of urology, patients diagnosed with renal carcinoma with evidence of extension from the kidney who are deemed healthy can undergo cytoreductive nephrectomy, metastasectomy, followed by systemic therapy.

Treatment of Metastatic RCC
The most well studied field of urological malignancies with regard to metastasectomy is renal cell carcinoma because of the resistance to chemotherapy or radiotherapy and the limited response to immunotherapy. Two decades ago, recombinant interleukin-2 received U.S. Food and Drug Administration (FDA) approval for the treatment of patients with advanced renal cancer and subsequently of patients with melanoma. The exact mechanism by which recombinant interleukine-2 and interferon-α modulate the immunological response, inducing long-term responses in metastatic renal cell carcinoma, is still not clear. Although targeted therapies represent a substantial improvement in patients with metastases, they are still not curative. Approved drugs include tyrosine kinase inhibitors (TKI) such as sunitinib, sorafenib and pazopanib, vascular endothelial growth factor inhibitors such as bevacizumab, and mammalian target of rapamycin (mTOR) inhibitors such as temsirolimus and everolimus.

Sunitinib is a multiple tyrosine kinase receptor inhibitor approved for the treatment of metastatic RCC and gastrointestinal stromal tumor. It is one of several agents (including sorafenib as the first-line agent and everonimus as the second-line agent) that target the activity of angiogenic growth factors and show favorable results in clinical trials involving patients with metastatic clear-cell RCC. The observation that inactivation of von Hippel-Lindau tumor suppressor gene results in hypoxia inducible factor activity and thereby increased expression of vascular endothelial growth factor A, platelet-derived growth factor A, and transforming growth factor β provided the rationale for targeting these pathways in clear-cell RCC. Objective response rate was 47% with sunitinib therapy but majority of patients experienced partial response or stabilization of disease, and only 3% demonstrated a complete response to treatment. Moreover, the median overall survival for patients with metastatic RCC who received sunitinib still was only slightly greater than 2 years.
**Predictive Factor for the Severe Case of Acute Bacterial Prostatitis**

Satoshi Yazawa\(^1\), Kent Kanao\(^1\), Eiji Kikuchi\(^1\), Goh Ohji\(^2\), Naoto Hosokawa\(^\text{a}^3\), Hirohiko Nagata\(^1\), Ryuichi Mizuno\(^3\), Ken Nakagawa\(^1\), Hitoshi Tanoguchi\(^6\), Yosuke Nakajima\(^8\), Mototsugu Oya\(^\text{a}^3\)

1) Department of Urology, Keio University, School of Medicine
2) Division of Infectious Disease Therapeutics Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine
3) Department of General Internal Medicine and Infectious Diseases, Kameda Medical Center
4) Department of Urology, Ishihara Kyodo Hospital
5) Department of Urology, Saiseikai Yokohamashi Tobu Hospital

**Introduction/Purpose:** Currently, there are few established evidences in the definitive classification on the severity of and clear indication for admission criteria for patients with Acute Bacterial Prostatitis (ABP). In this study, we evaluated presenting symptoms and clinical findings in large number of patients diagnosed with ABP, and assessed the factors associated with poor clinical course of ABP.

**Materials and Methods:** We retrospectively reviewed the records of 208 patients diagnosed with ABP at Saiseikai Yokohamashi Tobu Hospital (n=31), Ishihara Kyodo Hospital (n=58), and Keio University Hospital (n=119). The severe cases were defined as (1) prolonged shock state (24 hours or longer), (2) newly diagnosed shock after initiation of treatment, (3) positive blood culture, or (4) prostatic abscess (Rivers et al. NEJM 2001, Hooton et al. CID 2010, Fine et al. NEJM 1997). Patients who did not meet any of the above criteria were defined as non-severe cases. Patients were divided into the two groups; severe cases and non-severe cases. By comparing the two groups, we analyzed the independent factor associated with severe cases with ABP.

**Results:** The median age of our patients was 64.7 years. Forty-three patients were classified as severe case and 165 as non-severe case. Univariate analysis showed that (1) age \(\geq 65\) years, (2) past history of BPH, (3) use of a transurethral catheter, (4) past history of urinary retention, (5) complaint of pain on urination, (6) coma, (7) systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg, (8) heart rate \(\geq 120\) bpm, (9) body temperature \(\geq 38.0^\circ\text{C}\), (10) WBC >18,000/µl, (11) BUN >19 mg/dl, and (12) CRP were significantly associated with severe cases with ABP. Multivariate analysis showed that: (1) systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg, (2) WBC >18,000/µl, and (3) BUN >19 mg/dl were independently associated with severe cases with ABP.

**Conclusion:** Our results demonstrated that BP level at the initial diagnosis, WBC, and BUN count are the predictors for severe cases of ABP. These predictors might be helpful to identify the patients with ABP treated under hospitalization and with intensive care.
A case of quadruple malignancy of MALT lymphoma, colon cancer, gastric cancer, renal cell carcinoma in one patient

Tomohiro Kobayashi, Yukio Yoneda, Keiji Shimizu, Rikio Yoshimura
Osaka General Hospital of West Japan Railway Company

We report a case of metachronous quadruple cancer: MALT (Mucosa-Associated Lymphoid Tissue) lymphoma, colon cancer, gastric cancer, renal cell carcinoma in a 75-year-old man. He was admitted to our hospital in June 2011 because of melena. He diagnosed MALT lymphoma, stage IV, colon (primary), abdominal and around bladder lymph nodes, bone marrow. He performed chemotherapy (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisolone) for MALT lymphoma from July 2011. In January 2012, gastrointestinal endoscopy and colonoscopy were performed, and then gastric cancer and colon cancer were diagnosed. Right renal cell carcinoma was found on computed tomography (CT). Early ascending colon cancer was detected colonoscopy. Resection of gastric cancer and renal cell carcinoma were performed in March 2012. Pathologically, the gastric cancer was well-differentiated adenocarcinoma, T1a N0 M0 and stage I; the colon cancer was well-differentiated adenocarcinoma, T1a, N0, M0 and stage I, the renal cell carcinoma was clear cell renal cell carcinoma, G2, INF α, v (-), T1a N0 M0, and stage I. 18F-fluorodeoxy glucose positron emission tomography (FDG-PET) CT was performed, the result was no malignancy.

Multiple primary malignancies are defined as two or more malignancies in individual without any relationship between the tumors. Because of advances early detection, treatment, and supportive care for cancer, the number of cancer survivors has been gradually increasing, and this led to an increase in the possible occurrence of subsequent malignancies.

As the number of patients with multiple primary cancer is increasing. Cancer patients should be carefully examined given the possibility of multiple cancers.
Japan-Korea Urological Congress in Kagoshima, Japan